These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 32772481)
1. The role of topical imiquimod in melanoma cutaneous metastases: A critical review of the literature. Scarfì F; Patrizi A; Veronesi G; Lambertini M; Tartari F; Mussi M; Melotti B; Dika E Dermatol Ther; 2020 Nov; 33(6):e14165. PubMed ID: 32772481 [TBL] [Abstract][Full Text] [Related]
2. Regression of internal melanoma metastases following application of topical imiquimod to overlying skin. Miller AK; Dusing R; Meggison A; Aires D J Drugs Dermatol; 2011 Mar; 10(3):302-5. PubMed ID: 21369648 [TBL] [Abstract][Full Text] [Related]
3. [Topical treatment of melanoma skin metastases with imiquimod]. Sigüenza M; Pizarro A; Mayor M; Vidaurrázaga C; Miralles L; González-Beato M; Casado M Actas Dermosifiliogr; 2005 Mar; 96(2):111-5. PubMed ID: 16476347 [TBL] [Abstract][Full Text] [Related]
4. Topical treatment of melanoma skin metastases with imiquimod: a review. Sisti A; Sisti G; Oranges CM Dermatol Online J; 2015 Feb; 21(2):. PubMed ID: 25756475 [TBL] [Abstract][Full Text] [Related]
5. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series. Shi VY; Tran K; Patel F; Leventhal J; Konia T; Fung MA; Wilken R; Garcia MS; Fitzmaurice SD; Joo J; Monjazeb AM; Burrall BA; King B; Martinez S; Christensen SD; Maverakis E J Am Acad Dermatol; 2015 Oct; 73(4):645-54. PubMed ID: 26259990 [TBL] [Abstract][Full Text] [Related]
6. Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study. Read T; Webber S; Thomas J; Wagels M; Schaider H; Soyer HP; Smithers BM BMJ Open; 2017 Oct; 7(10):e016816. PubMed ID: 28988173 [TBL] [Abstract][Full Text] [Related]
7. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228 [TBL] [Abstract][Full Text] [Related]
8. Local cryosurgery and imiquimod: A successful combination for the treatment of locoregional cutaneous metastasis of melanoma: A case series. Rivas-Tolosa N; Ortiz-Brugués A; Toledo-Pastrana T; Baradad M; Traves V; Soriano V; Sanmartín V; Requena C; Martí R; Nagore E J Dermatol; 2016 May; 43(5):553-6. PubMed ID: 26660713 [TBL] [Abstract][Full Text] [Related]
9. Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod. Joseph RW; Cappel M; Tzou K; Bagaria S; Gilstrap C; Swaika A; Jambusaria-Pahlajani A Melanoma Res; 2016 Aug; 26(4):409-12. PubMed ID: 27138458 [TBL] [Abstract][Full Text] [Related]
10. Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature. Ellis LZ; Cohen JL; High W; Stewart L Dermatol Surg; 2012 Jun; 38(6):937-46. PubMed ID: 22338583 [TBL] [Abstract][Full Text] [Related]
11. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Florin V; Desmedt E; Vercambre-Darras S; Mortier L Invest New Drugs; 2012 Aug; 30(4):1641-5. PubMed ID: 21748297 [TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875 [TBL] [Abstract][Full Text] [Related]
13. [In-transit metastasis in melanoma: Efficacy of topical imiquimod combined with carbon dioxide laser or with electrocautery]. Elfatoiki FZ; Longvert C; Clerici T; Bourgault-Villada I; Roudier-Pujol C; Vasseur E; Saiag P Ann Dermatol Venereol; 2014 Feb; 141(2):106-10. PubMed ID: 24507204 [TBL] [Abstract][Full Text] [Related]
14. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Hesling C; D'Incan M; Mansard S; Franck F; Corbin-Duval A; Chèvenet C; Déchelotte P; Madelmont JC; Veyre A; Souteyrand P; Bignon YJ Br J Dermatol; 2004 Apr; 150(4):761-7. PubMed ID: 15099376 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. Turza K; Dengel LT; Harris RC; Patterson JW; White K; Grosh WW; Slingluff CL J Cutan Pathol; 2010 Jan; 37(1):94-8. PubMed ID: 19602071 [TBL] [Abstract][Full Text] [Related]
16. Assessing the Efficacy of Imiquimod Use in Patients With Persistent Locally Advanced Melanoma In Situ. Ward C; DePalo DK; Patel N; Carr M; Longbottom B; Cunningham K; Culbreth A; Reed R; Harkins A; Puleo C; Correa L; Seminario-Vidal L; Zager JS J Drugs Dermatol; 2023 May; 22(5):457-464. PubMed ID: 37133478 [TBL] [Abstract][Full Text] [Related]
17. A case of topical imiquimod induced fatigue. Raman J; Bisbee E; Missall TA; Saikaly SK J Dermatolog Treat; 2022 Dec; 33(8):3202-3204. PubMed ID: 36102924 [TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes of Melanoma In Situ Treated With Topical 5% Imiquimod Cream: A Retrospective Review. Park AJ; Paul J; Chapman MS; Samie FH Dermatol Surg; 2017 Aug; 43(8):1017-1022. PubMed ID: 28328708 [TBL] [Abstract][Full Text] [Related]
19. Management of cutaneous locoregional recurrences of melanoma: a new therapeutic perspective with imiquimod. Vereecken P; Mathieu A; Laporte M; Petein M; Velu T; Awada A; Heenen M Dermatology; 2003; 206(3):279-80. PubMed ID: 12673091 [No Abstract] [Full Text] [Related]
20. Use of imiquimod for residual acral melanoma. Sue GR; Hanlon A; Lazova R; Narayan D BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25188932 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]